This chart from T.Rowe Price illustrates the trend on a 10-year scale:
Over that time, the performance of the US Russell 1000 Growth Index has more than doubled that of its counterpart – the Russell 1000 Value Index.
But it’s the right end of the chart that’s caught the fund manager’s eye, where the MSCI Emerging Markets Value Index has returned close to nothing over the last 10 years.
And if the November trend extends into next year, that could be about to change.
“Unleashed pent-up global demand, increased fiscal spending, aggressive monetary policies, and higher energy prices could provide a strong backdrop for cyclical companies in EM,” T.Rowe Price said.
As the world recovers, The MSCI Emerging Markets Value Index could also benefit from broad downward pressure on the US dollar.
In terms of its price-action, the USD often acts as a ‘safe-haven’ currency. For example, it rose sharply during the economic shock caused by COVID-19.
However, other currencies (such as the Aussie dollar) have since risen to multi-year highs against the greenback.
“Ignored for nearly a decade, EM value companies may finally see more interest from investors as they dig for cyclical opportunities with very attractive valuations,” T.Rowe Price said.
The investment team also addressed the escalating trade tensions between Australia and China, which have generated “no shortage of negative headlines”.
However, they are not of the view that recent Chinese bans on a number of Australian industries will have a material effect on broader corporate earnings.
While coal exports were the latest to cop a ban, most of China’s trade constraints are focused on agricultural commodities.
Collectively, these make up “only a very small proportion” of Australia’s trade with China, T.Rowe Price said.
Conversely, “China would not be able to replace its iron ore imports easily either, given the high quality of Australia’s minerals and supply constraints in other global markets”.
For his part, the company’s head of Australian equities, Randal Jenneke, has taken some profits on Aussie iron ore miners following the recent rally.
While the fund’s global team is focused on EM Value stocks, Jenneke still likes the look of some high-growth tech names on the ASX, in an environment of low rates and low inflation.
T.Rowe Price favours Resmed (ASX:RMD) as one such play, with the medical device manufacturer “well placed to return to strong growth in its sleep apnea business over the next six to 12 months”.
Other stocks Jenneke said have similar tailwinds are Seek Group (ASX:SEK) and Aristocrat Leisure (ASX:ALL).
share
Link copied to clipboard
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox.
It's free. Unsubscribe whenever you want.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
Get the latest Stockhead news delivered free to your inbox
For investors, getting access to the right information is critical.
Stockhead’s daily newsletters make things simple: Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
Markets coverage, company profiles and industry insights from Australia’s best business journalists – all collated and delivered straight to your inbox every day.
It’s free. Unsubscribe anytime.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
I want the news:
Hear it first
Get the latest Stockhead news delivered free to your inbox.
Thanks! You’re subscribed, Stockhead news is coming your way soon.